Form 4: Hologic Director Acquires 3,190 Restricted Stock Units

Hologic Inc. Director Christiana Stamoulis reported the acquisition of 3,190 restricted stock units, increasing her beneficial ownership.

Summary

• Christiana Stamoulis, a Director of Hologic Inc. (HOLX), acquired 3,190 restricted stock units (RSUs).
• The transaction date for this acquisition was February 26, 2026.
• These RSUs will vest on the date of the 2027 Annual Meeting of Stockholders.
• Upon vesting, the RSUs will be settled in shares of Hologic common stock on a one-for-one basis.
• Following this transaction, Ms. Stamoulis beneficially owns a total of 50,526 shares of Hologic common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of a director's interests with shareholder value through equity compensation, which is a standard and healthy corporate governance practice.

Positives

• The acquisition of restricted stock units by a director aligns their interests with those of shareholders, indicating confidence in the company's future performance.
• The increase in beneficial ownership to 50,526 shares demonstrates a significant stake held by the director.

Future Outlook

The vesting of restricted stock units in 2027 indicates a long-term incentive structure for the director, aligning their future compensation with the company's performance over the coming year.

Industry Context

StockSavvy.ai notes that grants of restricted stock units are a common form of executive and director compensation across various industries, particularly in the healthcare technology sector where Hologic operates. This practice aims to incentivize long-term performance and align leadership interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially fostering long-term value creation.

Next Steps

• The 3,190 restricted stock units are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders.
• Upon vesting, the units will be settled in shares of Hologic common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a director as part of their compensation. While it indicates continued alignment of interests, it does not present new information that would fundamentally alter the investment thesis for Hologic Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Hologic, HOLX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership, Stock Grant